Rajter, 280 patient ivermectin late treatment PSM study: 46% lower mortality [p=0.05] and 64% lower ventilation [p=0.1] https://c19p.org/rajter
copied to clipboard
Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)
et al., Chest, doi:10.1016/j.chest.2020.10.009
Retrospective 280 hospitalized patients showing lower mortality with ivermectin (13.3% vs 24.5%), propensity matched odds ratio OR 0.47 [0.22-0.99], p=0.045.
|
risk of death, 46.0% lower, RR 0.54, p = 0.045, treatment 13 of 98 (13.3%), control 24 of 98 (24.5%), NNT 8.9, adjusted per study, odds ratio converted to relative risk, PSM.
|
|
risk of death, 66.9% lower, RR 0.33, p = 0.03, treatment 26 of 173 (15.0%), control 27 of 107 (25.2%), NNT 9.8, adjusted per study, odds ratio converted to relative risk, multivariate, primary outcome.
|
|
risk of mechanical ventilation, 63.6% lower, RR 0.36, p = 0.10, treatment 4 of 98 (4.1%), control 11 of 98 (11.2%), NNT 14, matched cohort excluding intubated at baseline.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Rajter et al., 10/13/2020, retrospective, propensity score matching, USA, North America, peer-reviewed, 6 authors, dosage 200μg/kg single dose.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.